Resources

2024 ∙ ACIP

GRADE of Protein subunit RSV vaccines (GSK Arexvy and Pfizer Abrysvo) in older adults

2024 ∙ ACIP

GRADE of Moderna mRNA RSV Vaccine (mResvia) in older adults

2024 ∙ NACI

NACI Interpretation Guide – Health Economics

2024 ∙ Eliza Dryer, Abigail Shefer, Shalini Desai, Lance Rodewald, Magdalena Bastias, Nathalie El Omeiri, Sidy Ndiaye, Kori Cook, Louise Henaff, Erin Kennedy

Development of a maturity assessment tool to evaluate and strengthen National Immunization Technical Advisory Groups (NITAGs)

2024 ∙ STIKO

Resolution on the STIKO recommendation for a standard vaccination against diseases caused by respiratory syncytial viruses (RSV) for persons ≥ 75 years of age and for the indication vaccination of persons aged 60 to 74 years with risk factors

2024 ∙ NACI

Statement on the prevention of respiratory syncytial virus disease in older adults

2024 ∙ ACIP

ACIP Evidence to Recommendations for Use of Protein Subunit RSV vaccines (GSK Arexvy or Pfizer Abrysvo) in All Adults Aged ≥75 years and in Adults Aged 60–74 at Increased Risk of Severe RSV Disease

2024 ∙ ACIP

ACIP Evidence to Recommendations for Use of Moderna RSV Vaccine (mResvia) in All Adults Aged ≥75 years and in Adults Aged 60–74 at Increased Risk of Severe RSV Disease

2024 ∙ NACI

Supplemental guidance from NACI on influenza vaccination in adults 65 years of age and older

2024 ∙ NACI

5192 results found

GRADE of Protein subunit RSV vaccines (GSK Arexvy and Pfizer Abrysvo) in older adults

GRADE of Moderna mRNA RSV Vaccine (mResvia) in older adults

NACI Interpretation Guide – Health Economics

Development of a maturity assessment tool to evaluate and strengthen National Immunization Technical Advisory Groups (NITAGs)

Resolution on the STIKO recommendation for a standard vaccination against diseases caused by respiratory syncytial viruses (RSV) for persons ≥ 75 years of age and for the indication vaccination of persons aged 60 to 74 years with risk factors

Statement on the prevention of respiratory syncytial virus disease in older adults

ACIP Evidence to Recommendations for Use of Protein Subunit RSV vaccines (GSK Arexvy or Pfizer Abrysvo) in All Adults Aged ≥75 years and in Adults Aged 60–74 at Increased Risk of Severe RSV Disease

ACIP Evidence to Recommendations for Use of Moderna RSV Vaccine (mResvia) in All Adults Aged ≥75 years and in Adults Aged 60–74 at Increased Risk of Severe RSV Disease

Supplemental guidance from NACI on influenza vaccination in adults 65 years of age and older

Addendum to the NACI statement on seasonal influenza vaccine for 2024-2025: Transition from quadrivalent to trivalent influenza vaccines